These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7923556)

  • 1. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice.
    Eiseman JL; Eddington ND; Leslie J; MacAuley C; Sentz DL; Zuhowski M; Kujawa JM; Young D; Egorin MJ
    Cancer Chemother Pharmacol; 1994; 34(6):465-71. PubMed ID: 7923556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
    Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
    Egorin MJ; Zuhowski EG; Sentz DL; Dobson JM; Callery PS; Eiseman JL
    Cancer Chemother Pharmacol; 1999; 44(4):283-94. PubMed ID: 10447575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii.
    Egorin MJ; Sentz DL; Rosen DM; Ballesteros MF; Kearns CM; Callery PS; Eiseman JL
    Cancer Chemother Pharmacol; 1996; 39(1-2):51-60. PubMed ID: 8995499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level].
    Fujita H; Okamoto M; Takao A; Mase H; Kojima H
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):653-8. PubMed ID: 7908791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice.
    Eiseman JL; Yuan ZM; Eddington ND; Sentz DL; Callery PS; Egorin MJ
    Cancer Chemother Pharmacol; 1996; 38(1):13-20. PubMed ID: 8603446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
    Innocenti F; Danesi R; Di Paolo A; Agen C; Nardini D; Bocci G; Del Tacca M
    Drug Metab Dispos; 1995 Jul; 23(7):713-7. PubMed ID: 7587959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
    Paxton JW; Young D; Evans SM; Kestell P; Robertson IG; Cornford EM
    Cancer Chemother Pharmacol; 1992; 29(5):379-84. PubMed ID: 1551177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of paclitaxel.
    Sonnichsen DS; Relling MV
    Clin Pharmacokinet; 1994 Oct; 27(4):256-69. PubMed ID: 7834963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method.
    Chen CL; Uckun FM
    Pharm Res; 1999 Aug; 16(8):1226-32. PubMed ID: 10468024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation.
    Wei Y; Xue Z; Ye Y; Wang P; Huang Y; Zhao L
    Biomed Chromatogr; 2014 Feb; 28(2):204-12. PubMed ID: 23893887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution.
    Kim SC; Yu J; Lee JW; Park ES; Chi SC
    J Pharm Biomed Anal; 2005 Sep; 39(1-2):170-6. PubMed ID: 16085137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
    Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
    Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
    Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
    Onkologie; 2002 Dec; 25(6):503-8. PubMed ID: 12566894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
    Kemper EM; Cleypool C; Boogerd W; Beijnen JH; van Tellingen O
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):173-8. PubMed ID: 14605863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.